These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 33686365)
1. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Noor R Curr Clin Microbiol Rep; 2021; 8(3):178-185. PubMed ID: 33686365 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
3. A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants? Noor R Curr Clin Microbiol Rep; 2021; 8(3):186-193. PubMed ID: 34249605 [TBL] [Abstract][Full Text] [Related]
4. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678 [TBL] [Abstract][Full Text] [Related]
5. A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic. Noor R Bull Natl Res Cent; 2022; 46(1):31. PubMed ID: 35194369 [TBL] [Abstract][Full Text] [Related]
6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
8. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2. Jamous YF; Alhomoud DA Cureus; 2023 Sep; 15(9):e45602. PubMed ID: 37868494 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. Noor R; Shareen S; Billah M Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
11. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use. Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358 [TBL] [Abstract][Full Text] [Related]
12. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines. Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604 [TBL] [Abstract][Full Text] [Related]
14. Review of COVID-19 Vaccines and Their Evidence in Older Adults. Teo SP Ann Geriatr Med Res; 2021 Mar; 25(1):4-9. PubMed ID: 33550776 [TBL] [Abstract][Full Text] [Related]
15. The COVID-19 pandemic: viral variants and vaccine efficacy. Ciotti M; Ciccozzi M; Pieri M; Bernardini S Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660 [TBL] [Abstract][Full Text] [Related]
17. An overview of current COVID-19 vaccine platforms. Nagy A; Alhatlani B Comput Struct Biotechnol J; 2021; 19():2508-2517. PubMed ID: 33936564 [TBL] [Abstract][Full Text] [Related]
18. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
19. A review on Promising vaccine development progress for COVID-19 disease. Belete TM Vacunas; 2020; 21(2):121-128. PubMed ID: 32837460 [TBL] [Abstract][Full Text] [Related]
20. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]